Order book crushes guidance; execution risk ahead

Q1 revenue +130.4% YoY; FY27 guidance 80% ±5%. Q1 pace supports beating annual target

23.6% is within 23–25% band (24% ±100 bps). Slight margin compression from 25.5% Q4 due to mix

Order book target was ₹5,000 Cr by FY27 year-end; achieved in Q1. Beat by ₹143 Cr

Kaiga 5&6 orders + refurb pipeline = ~₹800 Cr, unprecedented for company's nuclear division

Q1 at +130% pace. If sustained, would deliver >100% FY27 growth. Credible based on order book

FY27 target ₹5,000 Cr met by Q1 end (₹5,143 Cr). ₹800 Cr additional orders announced. De-facto upgrade in order visibility.

Q1 saw ₹684 Cr existing orders + ₹130–140 Cr refurb pipeline expected Q2. Total ~₹800 Cr unprecedented. Prior calls hinted hope; now materialized.

MD now explicitly targets doubling aerospace revenue in FY27 and ₹600–700 Cr by FY30. Prior call was more cautious on timelines.

First formal capex guidance provided: ₹500 Cr (70% clean energy, 30% other), split across FY27 and FY28. Q1 spent ~₹35 Cr.

New product revenue (ball screws, aerospace components) now ~₹100 Cr run-rate, ~50% of fuel-cell revenue. Diversification win vs prior single-product bets.

Today's ₹800 Cr orders execute next year (FY28). Kaiga 5&6: 1–3.5 years depending on order. Refurb: within 2 years. Execution ramp H2 FY27.

Through EPC vendors. MTAR participation will be much higher than Kaiga 5&6 because Mahi is 4 reactors vs 2 for Kaiga. Already qualified for multiple projects.

Better commercial terms, credit-term negotiation, delivery at customer premises for faster cash. Target 100 days by year-end. Organic improvements, not inorganic factoring (to protect margins).

70% clean energy, 30% other. Q1 spent ~₹35 Cr actual (₹80 Cr capitalized as CWIP). Phased over FY27 and FY28. 4–5x asset turnover minimum expected.

March 2027 commissioning. Phase 3 is multifold expansion (NDA prevents specifics). Ramp-up from April onwards. Capacity and manpower training ahead of execution.

Sustained and will grow more. Combination of ball screws (export + MNC contracts), aerospace components. Not just fuel-cell related; across sectors.

3–3.5 years overall. Some within 2 years. Total ~₹800 Cr. Execution starts H2 FY27, ramps from there. No cyclicality expected post-FY27.

70% clean energy (~₹350 Cr), 30% other (~₹150 Cr). Some capex fungible across sectors. Q1 ~₹35 Cr spent (actual), ₹80 Cr capitalized (CWIP).

₹45 Cr order, execute by March 2027. First batch 2–3 assemblies in progress. Potential requirement 8x order size (₹360 Cr+). Setting up dedicated facility.

Tenders floated for four 700 MW reactors. MTAR participation much higher than Kaiga (4 vs 2 reactors). Likely next FY. Cannot quantify TAM precisely; process-driven.

Contributed massively to PFBR (majority of critical assemblies). Now looking at additional reactors post-criticality. Great opportunity; details coming as info received. Direct with government.

All unwanted noise. We are progressing well, orders coming in consistently. Things moving in right direction. No issue at all.

Tejas actuators: ₹140–150 Cr opportunity. Nuclear: 60–70% wallet share vs NPCIL/DAE. Working on niche defense projects (can't detail). Numbers will grow; massive plan ahead for 4–6 reactors.

Short-cycle orders: mostly 1–2 years, some 6 months. Focus: execute fast. Majority short-cycle. Market share: we hold majority but can't disclose %. Demand very high.

Products: >₹1,000 Cr. Aerospace: ₹600–700 Cr. Based on roadmap and current programs ramping.

Q1 at +130% pace supports beating 80%. Management reaffirmed and added confidence ('will do better'). Order book beat suggests momentum.

Q1 delivered 23.6% within band. Mix headwind (aerospace/products lower margin vs nuclear) managed; capex investment in place.

70% clean energy, 30% other. Q1 ~₹35 Cr spent. Execution timeline risk: Phase 2 by Oct, Phase 3 by Mar 2027.

₹500 Cr capex over 2 years; Phase 2 by Oct, Phase 3 by Mar 2027. If delayed, revenue ramp into FY28, missing guidance.

Large MNC customer accounts for majority of clean-energy revenue. Capex slowdown, demand shift, or pricing pressure would materially impact.

₹800 Cr nuclear order book, but execution starts H2 FY27. Long-cycle projects; any slippage delays H2–Q4 ramp.

Tejas and MNC programs: targeting doubling aerospace revenue in FY27, with 10–15x volumes from FAC. FAC delays or customer delays would push ramp to FY28+.

Q1 gross margin 45.6% vs 47.7% YoY, due to revenue mix. Aerospace and products lower-margin than expected nuclear ramp.